A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999... Show more
The Aroon Indicator for AZNCF entered a downward trend on December 31, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 137 similar instances where the Aroon Indicator formed such a pattern. In of the 137 cases the stock moved lower. This puts the odds of a downward move at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZNCF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AZNCF broke above its upper Bollinger Band on January 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on January 06, 2026. You may want to consider a long position or call options on AZNCF as a result. In of 114 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for AZNCF just turned positive on January 07, 2026. Looking at past instances where AZNCF's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
AZNCF moved above its 50-day moving average on January 02, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AZNCF advanced for three days, in of 252 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.427) is normal, around the industry mean (9.607). P/E Ratio (31.600) is within average values for comparable stocks, (24.682). Projected Growth (PEG Ratio) (1.093) is also within normal values, averaging (1.998). Dividend Yield (0.017) settles around the average of (0.025) among similar stocks. P/S Ratio (5.112) is also within normal values, averaging (3.957).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AZNCF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsMajor